LON:HEMO Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis GBX 620 -20.00 (-3.13%) As of 12:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About Hemogenyx Pharmaceuticals Stock (LON:HEMO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HEMO alerts:Sign Up Key Stats Today's Range 620▼ 66950-Day Range 615▼ 82452-Week Range 133.05▼ 1,800Volume6,490 shsAverage Volume23,750 shsMarket Capitalization£42.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom. Read More Receive HEMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEMO Stock News HeadlinesHemogenyx Pharmaceuticals Distributes 2025 Annual Report and Confirms June AGM (HEMO)June 6, 2026 | uk.finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Notice of AGMJune 6, 2026 | finance.yahoo.comThe world's #2 gold miner is running on fumes [it has to buy]Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-largest miner running on fumes. Newmont's $15 billion purchase of Newcrest, the largest mining deal in history, still couldn't keep output growing, proof that majors must keep buying to survive. With record cash flows and shrinking mines, gold majors are positioned to launch a wave of acquisitions targeting the best junior assets.August 6 at 1:00 AM | Golden Portfolio (Ad)Hemogenyx Pharmaceuticals PLC Announces Institutional FundraiseApril 28, 2026 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Annual IND Report with FDAApril 14, 2026 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Tech Transfer Completion and Clinical Trial UpdateMarch 31, 2026 | finance.yahoo.comSMALL-CAP WINNERS & LOSERS: Hemogenyx raises funds for phase I trialsFebruary 10, 2026 | lse.co.ukHemogenyx Pharmaceuticals announces equity issuance and operational updatesDecember 18, 2025 | msn.comSee More Headlines HEMO Stock Analysis - Frequently Asked Questions How have HEMO shares performed this year? Hemogenyx Pharmaceuticals' stock was trading at GBX 578 at the start of the year. Since then, HEMO shares have increased by 7.3% and is now trading at GBX 620. How were Hemogenyx Pharmaceuticals' earnings last quarter? Hemogenyx Pharmaceuticals Plc (LON:HEMO) posted its quarterly earnings results on Thursday, April, 30th. The company reported ($170.60) earnings per share for the quarter. How do I buy shares of Hemogenyx Pharmaceuticals? Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Hemogenyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include 4D pharma (DDDD), genedrive (GDR), International Consolidated Airlines Group (IAG), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA). Company Calendar Last Earnings4/30/2026Today8/06/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:HEMO Previous SymbolLON:SILF CIKN/A Websilverfalconplc.com Phone44 79 0917 7311FaxN/AEmployees14Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (170.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£6.89 thousand Net MarginsN/A Pretax MarginN/A Return on Equity-2,807.75% Return on Assets-37.79% Debt Debt-to-Equity Ratio167.66 Current Ratio1.38 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 303.18 per share Price / Cash Flow2.05 Book ValueGBX 0.25 per share Price / Book2,516.66Miscellaneous Outstanding Shares6,800,000Free FloatN/AMarket Cap£42.16 million OptionableNot Optionable Beta1.53 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (LON:HEMO) was last updated on 8/6/2026 by MarketBeat.com Staff. From Our PartnersThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredThis AI fund sends investors payouts every ThursdayCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredA $5 stock inside Kennedy Space Center?A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | SponsoredA Wall Street Veteran's Weekly Trade for Any Market ConditionDave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...Base Camp Trading | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredThe Wall Street loophole regular traders are exploitingA rare market window is giving regular traders an edge over big money right now. Tim Sykes, who has trained...Tim Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
